A phase II clinical study of cancer vaccine with Survivin helper peptide for patients with advanced/recurrent colorectal cancers

ABSTRACT: Interventions: 1st and 2nd duration of therapy: Subcutaneous injection of Survivin-hepler pepitde (1 mg) vaccine, mixed with Montanide and OK432 (Picibanil; 0.02 KE), at every two weeks, repeated 4 times 3rdduration of therapy: Subcutaneous injection of Survivin-hepler pepitde (1 mg) vaccine, mixed with Montanide and OK432 (Picibanil; 0.02 KE), at every four weeks, repeated 4 times Primary outcome(s): Tumor response: Disease control rate (DCR), best over- all response assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) after Survivin helper peptide vaccine Study Design: Single arm Non-randomized

DISEASE(S): Survivin-expressing Advanced/recurrent Colorectal Cancer Patients Or Patients Who Refuse Standard Cancer Therapy

PROVIDER: 2622923 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR